Invega Trinza is the every-three-month formulation of paliperidone palmitate. It is the longer-interval sibling of Invega Sustenna (the monthly version). Approved by the FDA in 2015 for schizophrenia, it offers something genuinely new in psychiatry: an antipsychotic dose schedule of just four injections per year.
Invega Trinza is a paliperidone palmitate injection given every 3 months for patients already stabilised on the monthly form — designed for very long dosing intervals to support adherence and quality of life.
How it differs from Invega Sustenna
The active drug is the same — paliperidone palmitate. The difference is the formulation: Invega Trinza uses larger nanocrystals that dissolve more slowly, releasing paliperidone over approximately 13 weeks rather than 4 weeks. The injection volume is larger and is given into the deltoid or gluteal muscle.
The eligibility rule
Invega Trinza cannot be used as a starter. Per FDA labelling, patients must be adequately treated with Invega Sustenna for at least 4 months, with the last 2 months at the same dose, before being switched to Invega Trinza. The reason is that the monthly form is needed first to establish what dose the patient tolerates and responds to, and to be sure they don't have a delayed adverse reaction to paliperidone before being committed to a 3-month depot.
The dose conversion
The Invega Trinza dose is roughly 3.5 times the monthly Invega Sustenna dose, reflecting the 3-month dosing interval. The exact equivalent doses are specified in the FDA labelling and are decided by the prescriber.
Who Invega Trinza fits well
- Patients already stable on monthly Invega Sustenna
- Patients who value the convenience of 4 injections per year over 12
- Patients with stable life circumstances who can be relied on to attend the quarterly visits
- Patients for whom the monthly visit itself was a burden (transportation, work)
Who might want to stay on the monthly form
- Patients still being optimised — dose changes are easier with a 4-week reset
- Patients with unstable life circumstances where missing a 3-month appointment is more catastrophic than missing a 1-month appointment
- Patients who prefer more frequent contact with the clinic
Missed-dose window
The 3-month interval has a defined catch-up window. If the next injection is delayed beyond that window, the patient typically has to step back to monthly Invega Sustenna for a period to re-establish blood levels before resuming Invega Trinza. The exact protocols are specified in the FDA labelling and depend on how many weeks (or months) have passed.
Call the clinic immediately. The catch-up protocol depends precisely on how late the dose is — it is more complex than with the monthly form, and getting it wrong can lead to relapse or to dose-stacking.
Side effects
The side effect profile of Invega Trinza is essentially the same as Invega Sustenna and oral paliperidone — because it is the same drug. Patients won't typically discover new side effects on Trinza that they didn't already have on Sustenna; that is part of why a stable monthly course is required before switching.
The most common are:
- Hyperprolactinaemia (irregular periods, breast changes, sexual side effects)
- Weight gain and metabolic changes
- Akathisia and other EPS
- Sedation
- Mild orthostatic hypotension
- Injection-site discomfort, swelling, or a small lump
What's been published
The pivotal trial supporting Invega Trinza approval — published by Berwaerts et al. in JAMA Psychiatry in 2015 and indexed on PubMed — randomised stable patients on Invega Sustenna to either continue monthly injections or switch to Invega Trinza for one year. Time to relapse was significantly longer in the Trinza group than in placebo, and comparable to continuation of monthly Invega Sustenna. The trial established Invega Trinza as a viable maintenance option in stabilised patients.
The longer-interval option
For patients who tolerate Invega Trinza well, the manufacturer also markets Invega Hafyera — a 6-month formulation given just twice a year. Hafyera requires the same kind of stepwise establishment: oral paliperidone or Invega Sustenna first, then Invega Trinza, then Hafyera. The choice between intervals is highly individual and is decided with the prescriber.
The bigger picture
For the right patient, an injection every 3 months can transform the experience of being on antipsychotic medication. Daily reminders, weekly pharmacy trips, and the constant low-grade awareness of "did I take it?" all fade. The trade-off is that adjustments are slower and missed appointments are more consequential. Most people who do well on a quarterly LAI describe a quieter, more invisible relationship with their illness — which, for many, is the real goal of treatment.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.